DK0563329T3 - Angiogene peptider - Google Patents

Angiogene peptider

Info

Publication number
DK0563329T3
DK0563329T3 DK92904736T DK92904736T DK0563329T3 DK 0563329 T3 DK0563329 T3 DK 0563329T3 DK 92904736 T DK92904736 T DK 92904736T DK 92904736 T DK92904736 T DK 92904736T DK 0563329 T3 DK0563329 T3 DK 0563329T3
Authority
DK
Denmark
Prior art keywords
peptides
angiogenic
healing
platelet factor
repair
Prior art date
Application number
DK92904736T
Other languages
Danish (da)
English (en)
Inventor
Russel B Whitman
Robert Wohl
Ronald G Duff
Original Assignee
Curative Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curative Tech Inc filed Critical Curative Tech Inc
Application granted granted Critical
Publication of DK0563329T3 publication Critical patent/DK0563329T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK92904736T 1990-12-21 1991-12-20 Angiogene peptider DK0563329T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63182390A 1990-12-21 1990-12-21
PCT/US1991/009813 WO1992011021A1 (en) 1990-12-21 1991-12-20 Angiogenic peptides

Publications (1)

Publication Number Publication Date
DK0563329T3 true DK0563329T3 (da) 1998-12-07

Family

ID=24532905

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92904736T DK0563329T3 (da) 1990-12-21 1991-12-20 Angiogene peptider

Country Status (10)

Country Link
US (1) US5470831A (ja)
EP (1) EP0563329B1 (ja)
JP (1) JP3159705B2 (ja)
KR (1) KR100204400B1 (ja)
AT (1) ATE164167T1 (ja)
CA (1) CA2098921C (ja)
DE (1) DE69129121T2 (ja)
DK (1) DK0563329T3 (ja)
ES (1) ES2117045T3 (ja)
WO (1) WO1992011021A1 (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
WO1995000543A1 (en) * 1993-06-18 1995-01-05 Curative Technologies, Inc. Anti-inflammatory peptides
WO1997010839A1 (en) * 1995-09-19 1997-03-27 Texas Biotechnology Corporation Compositions and methods for inhibiting the binding of pecam
US6693081B2 (en) * 1995-09-26 2004-02-17 Osteopharm Inc. Bone stimulating factor
AU721034B2 (en) 1996-02-15 2000-06-22 Biosense, Inc. Catheter based surgery
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
US6342051B1 (en) * 1997-06-12 2002-01-29 Gholam A. Peyman Treatment of anoxic tissue with angiogenesis-inducing implants
ES2255155T3 (es) 1998-02-05 2006-06-16 Biosense Webster, Inc. Dispositivo para la administracion intracardiaca de farmacos.
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
US6211157B1 (en) 1998-05-01 2001-04-03 Sulzer Biologics, Inc. Protein mixtures to induce therapeutic angiogenesis
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US6329164B1 (en) * 1999-03-18 2001-12-11 Neuro Probe, Incorporated Method for using a cell activity assay apparatus
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
FR2814076B1 (fr) * 2000-09-21 2002-12-20 Centre Nat Rech Scient Agent angiogenique et ses utilisations
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
CA2498717A1 (en) 2002-09-13 2004-03-25 Ocular Sciences, Inc. Devices and methods for improving vision
AU2003291871A1 (en) * 2002-12-05 2004-06-23 Osteopharm Inc. Bone growth factor
US20060275303A1 (en) * 2003-02-27 2006-12-07 Robert Bals Modulating angiogenesis using LL-37/HCAP-18
US20050191286A1 (en) * 2004-02-09 2005-09-01 Gandy James B. Lyophilized platelet rich plasma for the use in wound healing (chronic or acute) and bone or tissue grafts or repair
WO2005108463A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
WO2005116729A2 (en) 2004-05-20 2005-12-08 Coopervision, Inc., Corneal onlays and wavefront aberration correction to enhance vision
FR2872040B1 (fr) * 2004-06-23 2006-09-22 Centre Nat Rech Scient Cnrse Utilisation cosmetique d'au moins un tetrapeptide naturel ac-n-ser-asp-lys-pro- ou un de ses analogues en tant qu'agent antivieillissement et restructurant de la peau
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US20060142198A1 (en) * 2004-07-02 2006-06-29 Wound Care Partners Llc Compositions for treating wounds and processes for their preparation
US20060004189A1 (en) * 2004-07-02 2006-01-05 James Gandy Compositions for treating wounds and processes for their preparation
US7883520B2 (en) 2006-04-10 2011-02-08 Forsight Labs, Llc Corneal epithelial pocket formation systems, components and methods
CA2698754A1 (en) * 2007-09-11 2009-03-19 Dorian Bevec Use of a peptide as a therapeutic agent
US20100184675A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
WO2010033207A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
KR101335203B1 (ko) 2010-03-26 2013-11-29 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
WO2012122524A1 (en) 2011-03-09 2012-09-13 Worden Charles E Wound healant system and method of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
WO1992013874A2 (en) * 1991-01-02 1992-08-20 Fox Chase Cancer Center Angiogenic peptides

Also Published As

Publication number Publication date
US5470831A (en) 1995-11-28
KR100204400B1 (ko) 1999-06-15
EP0563329B1 (en) 1998-03-18
WO1992011021A1 (en) 1992-07-09
ES2117045T3 (es) 1998-08-01
DE69129121D1 (de) 1998-04-23
EP0563329A4 (ja) 1994-12-21
CA2098921C (en) 2000-12-05
KR930703004A (ko) 1993-11-29
EP0563329A1 (en) 1993-10-06
ATE164167T1 (de) 1998-04-15
JP3159705B2 (ja) 2001-04-23
JPH06504064A (ja) 1994-05-12
CA2098921A1 (en) 1992-06-22
DE69129121T2 (de) 1998-11-19

Similar Documents

Publication Publication Date Title
DE69129121D1 (de) Angiogene peptide
Shen et al. Sulfated chitosan rescues dysfunctional macrophages and accelerates wound healing in diabetic mice
Uludag et al. Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: a correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model
AU753816B2 (en) Recombinant fibronectin-based extracellular matrix for wound healing
Haverstock et al. Cigarette smoking and bone healing: implications in foot and ankle surgery
ES2375413T3 (es) Fragmentos peptídicos para inducir la síntesis de proteínas de la matriz extracelular.
EP0535091B1 (en) Osteoinductive pharmaceutical formulations
US7579322B2 (en) Compositions and methods for promoting myocardial and peripheral angiogenesis
ATE142693T1 (de) Herstellung des vaskulären endothelialen zellwachstumsfaktors
WO1991015222A2 (en) Method of predisposing mammals to accelerated tissue repair
EA003857B1 (ru) Пептидная фармацевтическая композиция и способ повышения эластичности ткани
US5155038A (en) Use of thrombospondin to promote wound healing
CA2690734A1 (en) Polypeptides and methods of use
McPherson The utility of collagen-based vehicles in delivery of growth factors for hard and soft tissue wound repair
EP0437281A1 (en) Composition comprising acidic fibroblast growth factor (aFGF)
BRPI0720874B1 (pt) composições compreendendo peptídeos bioativos curtos para modulação celular e imunológica
DE69634564D1 (de) Peptide des tsp-i-rezeptors cd36 zur behandlung von krankheiten welche durch eine fehlregulation von tgf-beta1 verursacht werden
CA2321933C (en) Fibronectin peptides-based extracellular matrix for wound healing
US6180610B1 (en) Tetrapeptide
JP3229643B2 (ja) 育毛促進剤
Joerring et al. Changes in collagen metabolites in serum after cemented hip and knee arthroplasty
DiPietro et al. The Role of Thrombospondin in Angiogenesis
DiPietro Thrombospondin and Angiogenesis
Pang et al. Articles in PresS. J Appl Physiol (October 28, 2010). doi: 10.1152/japplphysiol. 00945.2010
Biloklytska et al. The Osteoinductive Properties And Influence of “Emdogain”(Straumann) on Colony-Forming Properties of Human Osteogenous Progenitor Bone Marrow Cells Ex vivo